Dengvaxia market seen reaching $473.95 million by 2030

The Dengvaxia vaccine market is projected to grow from $213.36 million in 2025 to $250.81 million in 2026, driven by dengue outbreaks, broader vaccination campaigns and rising travel. The market could nearly double again by 2030 as climate change, public health funding and immunization programs expand.

Why it matters: - Dengvaxia sits at the center of a growing public health response to dengue fever, which is spreading across more regions as mosquito ranges expand. - The market outlook signals more demand for vaccination programs in endemic countries and for travelers headed to dengue-risk areas.

What happened: - The Business Research Company published its Dengvaxia Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report says the Dengvaxia market will rise from $213.36 million in 2025 to $250.81 million in 2026. - The report projects the market will reach $473.95 million by 2030. - The report says Asia-Pacific held the largest market share in 2025. - The report forecasts Latin America will be the fastest-growing region over the coming years. - The report includes coverage of Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report. - View the full market report.

The details: - The report pegs 2025-2026 growth at a 17.6% compound annual growth rate. - The forecast through 2030 implies a 17.2% CAGR. - The report links recent market growth to recurring dengue outbreaks, high disease burden in tropical regions, government vaccination programs, limited treatment options and rising public health awareness. - Future growth is expected to come from broader vaccination coverage, climate change-driven expansion of mosquito habitats, stronger public health funding, improved vaccine delivery systems and higher travel-related immunization demand. - The report highlights expanded dengue vaccination initiatives, stronger prevention efforts for endemic diseases, public health campaigns, more monitoring of mosquito-borne illness and vaccination programs targeting children and adolescents. - Dengvaxia is a recombinant vaccine designed to protect against dengue fever, a viral infection spread by Aedes mosquitoes. - The vaccine is intended to stimulate the immune system, help prevent dengue infection and reduce severe complications. - Dengvaxia is positioned as a public health tool in regions where dengue is widespread. - Rising dengue cases remain a key demand driver for the vaccine market. - Dengue can cause flu-like symptoms and, in severe cases, dengue hemorrhagic fever or dengue shock syndrome. - Climate change, urban growth, international travel and expanded mosquito breeding habitats have helped push case counts higher worldwide. - The CDC reported more than 9.7 million dengue cases in the Americas in 2024, up from 4.6 million in 2023. - Puerto Rico declared a public health emergency after 1,498 cases, while 745 cases were reported among travelers returning to the United States. - International travel is also boosting demand for preventive vaccination as people move between dengue-endemic and non-endemic regions. - The UK Office for National Statistics reported international visits rose from 31.2 million in 2022 to 38.0 million in 2023. - Higher healthcare spending is another support for the market because governments and private-sector buyers are funding more vaccination programs. - UK total healthcare spending rose 5.6% in nominal terms from 2022 to 2023, after 0.9% growth in the prior year. - The report also says more healthcare spending can help expand immunization efforts using Dengvaxia.

Between the lines: - The forecast reflects a market pulled by disease pressure on one side and better funding and delivery systems on the other. - Climate change appears in the report as a structural growth factor, not just a short-term outbreak driver. - Travel demand adds a second commercial use case beyond endemic-country vaccination campaigns.

What's next: - The report expects vaccination coverage to widen as governments and health systems respond to continued dengue risk. - Market growth will likely depend on how fast countries expand immunization programs and improve vaccine delivery. - Regional momentum in Latin America could sharpen as dengue burden rises and prevention efforts scale up. - The Business Research Company also says the 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics, and updated trend analysis.

The bottom line: - Dengvaxia is moving from a niche vaccine market into a faster-growing public health category, with outbreaks, travel and climate-driven mosquito expansion all pushing demand higher.